NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors
- 1 May 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (9) , 1846-1860
Abstract
Determining mechanisms of resistance to αPD-1/PD-L1 immune-checkpoint immunotherapy is key to developing new treatment strategies. Cancer-associated fibroblasts (CAF) have many tumor-promoting functions and promote immune evasion through multiple mechanisms, but as yet, no CAF-specific inhibitors are clinically available. Here we generated CAF-rich murine tumor models (TC1, MC38, and 4T1) to investigate how CAFs influence the immune microenvironment and affect response to different immunotherapy modalities [anticancer vaccination, TC1 (HPV E7 DNA vaccine), αPD-1, and MC38] and found that CAFs broadly suppressed response by specifically excluding CD8+ T cells from tumors (not CD4+ T cells or macrophages); CD8+ T-cell exclusion was similarly present in CAF-rich human tumors. RNA sequencing of CD8+ T cells from CAF-rich murine tumors and immunochemistry analysis of human tumors identified significant upregulation of CTLA-4 in the absence of other exhaustion markers; inhibiting CTLA-4 with a nondepleting antibody overcame the CD8+ T-cell exclusion effect without affecting Tregs. We then examined the potential for CAF targeting, focusing on the ROS-producing enzyme NOX4, which is upregulated by CAF in many human cancers, and compared this with TGFβ1 inhibition, a key regulator of the CAF phenotype. siRNA knockdown or pharmacologic inhibition [GKT137831 (Setanaxib)] of NOX4 “normalized” CAF to a quiescent phenotype and promoted intratumoral CD8+ T-cell infiltration, overcoming the exclusion effect; TGFβ1 inhibition could prevent, but not reverse, CAF differentiation. Finally, NOX4 inhibition restored immunotherapy response in CAF-rich tumors. These findings demonstrate that CAF-mediated immunotherapy resistance can be effectively overcome through NOX4 inhibition and could improve outcome in a broad range of cancers. Significance: NOX4 is critical for maintaining the immune-suppressive CAF phenotype in tumors. Pharmacologic inhibition of NOX4 potentiates immunotherapy by overcoming CAF-mediated CD8+ T-cell exclusion. Graphical http://cancerres.aacrjournals.org/content/canres/80/9/1846/F1.large.jpg. See related commentary by Hayward, p. 1799 Graphical AbstractKeywords
All Related Versions
Funding Information
- Cancer Research UK (A203904, A20256, A27989)
- Cancer Research UK (MR/P013414/1)
This publication has 65 references indexed in Scilit:
- Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effectsJournal of Clinical Investigation, 2012
- Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumorsJournal of Clinical Investigation, 2012
- Hyaluronan and versican in the control of human T-lymphocyte adhesion and migrationMatrix Biology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic CancerScience, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- TopHat: discovering splice junctions with RNA-SeqBioinformatics, 2009
- Ultrafast and memory-efficient alignment of short DNA sequences to the human genomeGenome Biology, 2009
- WGCNA: an R package for weighted correlation network analysisBMC Bioinformatics, 2008
- TGF-β: A Master of All T Cell TradesCell, 2008